RMEI, PIM jointly sponsor virtual lecture to address the need for education on ALL in AYAs

Mar 5 2010

Currently, no definitive standard of care exists for adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL). Recent research suggests that AYAs treated with pediatric treatment protocols have better outcomes than those treated with adult treatment protocols. It is important that healthcare professionals working with this unique patient population understand and apply evidence-based treatment strategies for ALL in order to maximize patient outcomes.

To address the need for current education on ALL in adolescents and young adults, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education virtual lecture titled Acute Lymphoblastic Leukemia in Adolescents and Young Adults: Strategies for Improved Patient Care. This activity, which is supported by an educational grant from Enzon Pharmaceuticals, is certified for physicians, nurses and pharmacists.

Lewis B. Silverman, MD, from the Dana-Farber Cancer Institute, Children's Hospital Boston and Harvard Medical School in Boston, Massachusetts, serves as faculty for this virtual lecture.